Pulse Biosciences Inc
NASDAQ:PLSE
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
US |
Pulse Biosciences Inc
NASDAQ:PLSE
|
400.9m USD | -11.1 | ||
US |
Abbott Laboratories
NYSE:ABT
|
181.9B USD | 25.5 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.7B USD | 83 | ||
US |
Stryker Corp
NYSE:SYK
|
126.5B USD | 36.4 | ||
IE |
Medtronic PLC
NYSE:MDT
|
112.6B USD | 17.4 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
109.4B USD | 44.2 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.6B USD | 20 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
60.2B EUR | 25.6 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
54.3B USD | 60.6 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
378.2B CNY | 30 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.4B USD | 64 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.